JP2021531276A5 - - Google Patents
Info
- Publication number
- JP2021531276A5 JP2021531276A5 JP2021502545A JP2021502545A JP2021531276A5 JP 2021531276 A5 JP2021531276 A5 JP 2021531276A5 JP 2021502545 A JP2021502545 A JP 2021502545A JP 2021502545 A JP2021502545 A JP 2021502545A JP 2021531276 A5 JP2021531276 A5 JP 2021531276A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- idua
- expression vector
- immunosuppressive therapy
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024040767A JP2024095680A (ja) | 2018-07-18 | 2024-03-15 | 完全ヒトグリコシル化ヒトα－Ｌ－イズロニダーゼ（ＩＤＵＡ）を用いたムコ多糖症Ｉ型の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862699923P | 2018-07-18 | 2018-07-18 | |
| US62/699,923 | 2018-07-18 | ||
| PCT/US2019/042205 WO2020018665A1 (en) | 2018-07-18 | 2019-07-17 | Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idus) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024040767A Division JP2024095680A (ja) | 2018-07-18 | 2024-03-15 | 完全ヒトグリコシル化ヒトα－Ｌ－イズロニダーゼ（ＩＤＵＡ）を用いたムコ多糖症Ｉ型の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021531276A JP2021531276A (ja) | 2021-11-18 |
| JP2021531276A5 true JP2021531276A5 (https=) | 2022-07-26 |
Family
ID=69164759
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502545A Pending JP2021531276A (ja) | 2018-07-18 | 2019-07-17 | 完全ヒトグリコシル化ヒトα−Ｌ−イズロニダーゼ（ＩＤＵＡ）を用いたムコ多糖症Ｉ型の治療 |
| JP2024040767A Pending JP2024095680A (ja) | 2018-07-18 | 2024-03-15 | 完全ヒトグリコシル化ヒトα－Ｌ－イズロニダーゼ（ＩＤＵＡ）を用いたムコ多糖症Ｉ型の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024040767A Pending JP2024095680A (ja) | 2018-07-18 | 2024-03-15 | 完全ヒトグリコシル化ヒトα－Ｌ－イズロニダーゼ（ＩＤＵＡ）を用いたムコ多糖症Ｉ型の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210275647A1 (https=) |
| EP (1) | EP3823590A4 (https=) |
| JP (2) | JP2021531276A (https=) |
| KR (1) | KR20210034037A (https=) |
| AU (1) | AU2019306236A1 (https=) |
| BR (1) | BR112021000830A2 (https=) |
| CA (1) | CA3106651A1 (https=) |
| IL (1) | IL280198B2 (https=) |
| SG (1) | SG11202100423YA (https=) |
| WO (1) | WO2020018665A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3068328A1 (en) | 2017-07-06 | 2019-01-10 | The Trustees Of The University Of Pennsylvania | Aav9-mediated gene therapy for treating mucopolysaccharidosis type i |
| KR102883778B1 (ko) | 2017-09-22 | 2025-11-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Ii형 점액다당류증의 치료를 위한 유전자 요법 |
| US20190114858A1 (en) * | 2017-10-16 | 2019-04-18 | Raritan Americas, Inc. | System for controlling access to an equipment rack and intelligent power distribution unit and control unit used therein |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001269923A1 (en) * | 2000-06-19 | 2002-01-02 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| DE60329724D1 (de) * | 2002-06-07 | 2009-11-26 | Waratah Pharmaceuticals Inc | Methoden und Kompositionen um Diabetes zu behandeln |
| JP5385143B2 (ja) * | 2006-09-21 | 2014-01-08 | ザ スクリプス リサーチ インスティチュート | 真正細菌における選択的に硫酸化された蛋白質の遺伝的にプログラムされた発現 |
| EP3230438B1 (en) * | 2014-12-12 | 2024-12-04 | University of Copenhagen | N-glycosylation |
| HK1256341A1 (zh) * | 2015-05-15 | 2019-09-20 | 明尼苏达大学董事会 | 用於治疗性递送到中枢神经系统的腺相关物 |
| CA3012195A1 (en) * | 2016-02-03 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type i |
| EP3411484B1 (en) * | 2016-02-05 | 2023-10-04 | Emory University | Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid |
| JP2020500928A (ja) * | 2016-11-15 | 2020-01-16 | リジェネクスバイオ インコーポレイテッド | Ｍｐｓｉおよびｍｐｓｉｉならびに他の神経障害において神経機能を改善するための方法 |
| KR20250022877A (ko) * | 2017-01-31 | 2025-02-17 | 리젠엑스바이오 인크. | 완전히-인간 글리코실화된 인간 알파-l-이두로니다아제(idua)를 이용한 뮤코다당증 1형의 치료 |
-
2019
- 2019-07-16 IL IL280198A patent/IL280198B2/en unknown
- 2019-07-17 US US17/260,732 patent/US20210275647A1/en active Pending
- 2019-07-17 JP JP2021502545A patent/JP2021531276A/ja active Pending
- 2019-07-17 BR BR112021000830-6A patent/BR112021000830A2/pt not_active Application Discontinuation
- 2019-07-17 AU AU2019306236A patent/AU2019306236A1/en not_active Abandoned
- 2019-07-17 WO PCT/US2019/042205 patent/WO2020018665A1/en not_active Ceased
- 2019-07-17 CA CA3106651A patent/CA3106651A1/en active Pending
- 2019-07-17 EP EP19837268.2A patent/EP3823590A4/en active Pending
- 2019-07-17 KR KR1020217004709A patent/KR20210034037A/ko active Pending
- 2019-07-17 SG SG11202100423YA patent/SG11202100423YA/en unknown
-
2024
- 2024-03-15 JP JP2024040767A patent/JP2024095680A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508289A5 (https=) | ||
| US12274743B2 (en) | Nucleic acid vaccines | |
| JP2021531276A5 (https=) | ||
| JP6896050B2 (ja) | ＴＡＴｋ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用 | |
| US20240307522A1 (en) | Compositions and methods for the prevention and/or treatment of covid-19 | |
| US11274158B2 (en) | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | |
| JP2017052783A5 (https=) | ||
| JP2019522989A (ja) | ＴＡＴκ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用 | |
| JP2024095680A5 (https=) | ||
| Madrigal et al. | Regulation of MCP‐1 production in brain by stress and noradrenaline‐modulating drugs | |
| CN104168910A (zh) | 肽及其用途 | |
| AU2022233960A1 (en) | Alpha-1-antitrypsin (aat) in the treatment and/or prevention of neurological disorders | |
| US20200360364A1 (en) | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using chrna6 activators | |
| KR20210078428A (ko) | 중추신경계 통증신호 제어를 통한 암유발 통증 완화 방법 | |
| CN108096568A (zh) | A型肉毒毒素在抗抑郁症中的应用 | |
| Xie et al. | Atopic Dermatitis: Updated Insights Into Pathophysiology and Emerging Therapies | |
| Rui et al. | Shensiqigui tablets alleviate bleomycin-induced pulmonary fibrosis by inhibiting the hedgehog/wnt-β-catenin pathway | |
| US20260035408A1 (en) | WKYMVm peptide analogues having six residues and uses thereof | |
| Crosson et al. | Heather Melichar | |
| WO2023201133A1 (en) | Cell therapy for alzheimer's disease | |
| Tayebati et al. | (Neuro) transmitter systems in circulating immune cells: a target of immunopharmacological interventions? | |
| HK40072892A (en) | Nucleic acid vaccines | |
| CN119280206A (zh) | 精胺在制备抗抑郁药中的应用 | |
| van der Kleij et al. | Significance of Sensory Neuropeptides and the Immune Response | |
| hoon Lee | The picture theory of eight pathways of COVID-19 in the real world |